Subscribe to RSS
DOI: 10.1055/s-2001-15685
Bedeutung der Komplementärmedizin am Beispiel der Hagebutte
Importance of Complementary Medicine Exemplified by the Use of Rose-hipPublication History
Publication Date:
31 December 2001 (online)
Zusammenfassung
Hagebutten entstehen aus den Blüten der Wildrose (Rosa canina) und sind ein verbreitetes Haus- und Naturmittel. Grundlagenstudien zeigen, dass Hagebuttenextrakte die Lipid-Oxidation in vitro hemmen und die Chemotaxis und Chemolumineszenz von Leukozyten reduzieren.
In klinischen Studien wurde gezeigt, dass der Serumspiegel von C-reaktivem Protein (CRP) und Creatinin bei gesunden Probanden und Patienten mit Osteoarthritis, die das Hagebuttenpulver einnahmen, gesenkt wurde. Zudem wurden physische Symptome von den Patienten mit Osteoarthritis gemildert. In einer kontrollierten randomisierten Studie bei Patienten mit Arthritis sank in der Gruppe, die das Hagebuttenpulver einnahm, nicht nur das Schmerzempfinden; auch die Flexion der Hüfte konnte deutlich verbessert werden.
Die antiinflammatorischen Eigenschaften machen die Hagebutte zu einem geeigneten Naturmittel bei der Behandlung von Arthritis. Welche Wirkstoffe im Einzelnen an diesem Prozess beteiligt sind, bleibt noch zu klären. Hinweise sprechen darauf, dass neben dem hohen Vitamingehalt Flavonoide wirksam sein könnten.
Importance of Complementary Medicine Exemplified by the Use of Rose-hip
Rose-hips develop from blossoms of the wild rose (rosa canina) and are a popular natural remedy. Laboratory experiments have shown that rose-hip extract inhibits lipid oxidation in vitro and reduces the chemotaxis and chemoluminescence of leucocytes.
In clinical studies serum CRP- und creatinin levels declined in healthy subjects and patients with osteoarthritis under rose-hip treatment. Additionally patients suffering from osteoarthritis reported that physical symptoms declined. Data from a randomised controlled trial indicate not only that pain significantly declined but also flexion of the hip improved in the active treatment group.
The anti-inflammatory properties of rose-hip are useful as a natural treatment in patients with osteoarthritis. It remains to be proven which of the components are responsible for these effects. There is some evidence that in addition to the high vitamin content flavonoids may be actively involved.
Key words
Rose-hip - Rosa canina - Osteoarthitis - CRP - Anti-inflammatory
Literatur
- 1 Flintrop J. Alternative Arzneimittel - „83 Prozent der Patienten wollen diese Präparate”. Deutsches Ärzteblatt. 1999; 25 1701
- 2 Steigert A. Phytotherapie. Via Medici. 1996; 4
- 3 Kraft K. Phytotherapie - Checklisten der aktuellen Medizin. Stuttgart; Thieme 2000
- 4 Gabius H J, Andre S, Kaltner H, Siebert H C, von der Lieth C W, Gabius S. Mythos Mistel-Anspruch, Wirklichkeit und prüfbare Perspektive. Z Ärztl Fortbild Jena. 1996; 90/2 103-110
- 5 Weihmayr T, Ernst E. Die therapeutische Wirksamkeit von Crataegus. Fortschr Med. 1996; 114 (1-2): 27-29
- 6 Spiro M, Chen S C. Rose-hip tea: Equilibrium and kinetic study of L-ascorbic acid extraction. Food Chem. 1993; 48/1 39-45
- 7 Hodisan T, Socaciu C, Ropan I, Neamtu G. Carotenoid composition of Rosa canina fruits determined by thin-layer chromatography and high-performance liquid chromatography. J Pharma Biomed Anal. 1997; 16/3 521-528
- 8 Chen S C, Spiro M. Rose-hip tea: Equilibrium and kinetic study of mineral ion extraction. Food Chem. 1993; 48/1 47-50
- 9 Bitsch J. Pflanzliche Phenole und ihre gesundheitliche Wirkung. Vita Min Spur. 1999; 14 16-20
- 10 Karakaya S, Nehir S. Quercetin, luteolin, apigenin and kaempferol contents of some foods. Food Chem. 1999; 66/3 289-292
- 11 Lengfelder W. Anti-oxidative Vitamine: Prävention von Kardiovaskulären Erkrankungen. Dtsch Med Wschr. 1998; 123 1014-1017
- 12 Diaz M N, Frei B, Vita J A, Keaney J r JF. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997; 337/6 408-416
- 13 Stampfer M J, Hennekens C J, Manson J E, Colditz G A, Rosner B, Willett W C. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med. 1993; 328/20 1444-1449
- 14 Kushi L H, Folsom A R, Prineas R J, Mink P J, Wu Y, Bostick R M. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996; 334/18 1156-1162
- 15 Rimm E B, Stampfer M J, Ascherio A, Giovannucci E, Colditz G A, Willett W C. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328/20 1450-1456
- 16 The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group . The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994; 330/15 1029-1035
- 17 Stephens N G, Parsons A, Schofield P M, Kelly F, Cheeseman K, Mitchinson M J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347/900 781-786
- 18 Omenn G S, Goodman G E, Thornquist M D. et al . Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334/18 1150-1155
- 19 Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342/3 154-160
- 20 Hertog M G, Feskens E J, Hollman P C, Katan M B, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly. Lancet. 1993; 342/8878 1007-1011
- 21 Hertog M G, Kromhout D, Aravanis C. et al . Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995; 155/4 381-386
- 22 Levkovith J. Cyclooxygenase-2 specificity and ist clinical Implications. Am J Med. 1999; 106 53-60
- 23 Devaraj S, Jialal I. Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Throm Vasc Biol. 1999; 19/4 1125-1133
- 24 Cao X, Evans P, Trajikvoski V, Uggla M, Halliwell B. Antioxidant effects of crude phenolic extracts of rose hips. Polyphenols, Wine and Health Symposium. April 14-16 Bordeaux, France; 1999: 21-25
- 25 Kharazmi A, Winther K. Rose-hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory prameters in vivo. Inflammopharmacol 1999 0/0: 1-10
- 26 Yesilada E, Ustun O, Sezik E, Takaishi Y, Ono Y, Honda G. Inhibitory effects of Turkish folk remedies on inflammatory cytokines: Interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha. J Ethnopharmacol. 1997; 58/1 59-73
- 27 Grases F, Masarova L, Costa B auza A, March J G, Prieto R, Tur J A. Effect of „Rosa Canina” infusion and magnesium on the urinary risk factors of calcium oxalate urolithiasis. Planta Med. 1992; 6/58 509-512
- 28 Morrow D A, Rifai N, Antman E M. et al . C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Amer Coll Cardiol. 1998; 31 1460-1465
- 29 Koenig W, Sund M, Frohlich M. et al . CRP, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburg Cohort Study 1984-92. Circulation. 1999; 2 237-242
- 30 Winther K, Kharazmi A, Rein E. Rose-hip given as standardised dry powder exerts anti-inflammatory and cell-preserving properties in humans. 2nd International Congress on Coronary Artery Disease Florence, Italy; 1999
- 31 Racek J, Herynkova R, Holecek V, Jerabek Z, Slama V. Influence of antioxidants on the quality of stored blood. Vox Sanguinis. 1997; 1/72 16-19
- 32 Winther K, Rein E, Kharazmi A. The anti-inflammatory properties of rose-hip. Inflammopharmacol. 1999; 7/1 63-68
- 33 Warholm O, Skaar S, Hedman E, Molmer H M, Eik L. Hyben Vital, a herbal remedy, reduces pain and stiffness of the hip, in a group of patients suffering from severe osteoarthrosis. The 9th APLAR Congress of Rheumatology Bejing, China; May 21-26th 2000
Prof. Stefan N. Willich
Institut für Sozialmedizin und
Epidemiologie
Universitätsklinikum
Charité
Humboldt-Universität zu Berlin
10098 Berlin
Email: stefan.willich@charite.de